Expands international mental property protection in markets with excessive breast most cancers incidence
New patent will present IP safety of Breast Most cancers Vaccine in China into 2040
SAN JOSE, Calif., Oct. 20, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Firm”) (NASDAQ: ANIX), a biotechnology firm targeted on the remedy and prevention of most cancers, in the present day introduced that the Chinese language Nationwide Mental Property Administration (CNIPA) has issued Patent Quantity ZL2020800215666, overlaying key elements of the Firm’s breast most cancers vaccine expertise.
Anixa’s breast most cancers vaccine, developed in collaboration with Cleveland Clinic, represents a novel method to the prevention and remedy of breast most cancers. Anixa’s vaccine is predicated on immunizing in opposition to human α-lactalbumin, a protein related to lactation that’s aberrantly expressed in sure kinds of breast most cancers. This “retired” protein vaccine technique goals to selectively prime the immune system to forestall tumor formation whereas avoiding hurt to regular tissue. The vaccine was invented at Cleveland Clinic, and this patent—together with others associated to this expertise—has been solely licensed to Anixa Biosciences.
This patent issuance builds upon the Firm’s broad and increasing mental property portfolio, extending foundational patent safety for the breast most cancers vaccine program into the 2040s in a number of jurisdictions all through the world. By reinforcing its international patent property, Anixa is laying the groundwork for future worldwide growth and commercialization methods.
“This newly issued patent additional demonstrates the novelty and potential of our breast most cancers vaccine,” said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. “As we proceed advancing medical growth within the U.S., this patent additional strengthens our skill to pursue strategic international alternatives in areas with a excessive incidence of breast most cancers.”
A Part 1 medical trial of Anixa’s breast most cancers vaccine has been lately accomplished and Cleveland Clinic will current full medical outcomes on the San Antonio Breast Most cancers Symposium on December 11, 2025.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology firm targeted on the remedy and prevention of most cancers. Anixa’s therapeutic portfolio consists of an ovarian most cancers immunotherapy program being developed in collaboration with Moffitt Most cancers Middle, which makes use of a novel sort of CAR-T, often called chimeric endocrine receptor-T cell (CER-T) expertise. This expertise is differentiated from different cell therapies because the pure ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell as an alternative of an antibody fragment. Moffitt is a world chief in most cancers immunotherapy therapies, pioneering next-generation cell therapies resembling CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the facility of the immune system. The Firm’s vaccine portfolio consists of vaccines being developed in collaboration with Cleveland Clinic to deal with and forestall breast most cancers and ovarian most cancers, in addition to further most cancers vaccines to deal with many intractable cancers, together with excessive incidence malignancies in lung, colon, and prostate. These vaccine applied sciences give attention to immunizing in opposition to “retired” proteins which have been discovered to be expressed in sure types of most cancers. The breast and ovarian most cancers vaccines had been developed at Cleveland Clinic and solely licensed to Anixa. Cleveland Clinic is entitled to royalties and different commercialization revenues from the Firm associated to those vaccine applied sciences. Anixa’s distinctive enterprise mannequin of partnering with world-renowned analysis establishments on all levels of growth permits the Firm to repeatedly look at rising applied sciences in complementary fields for additional growth and commercialization. To be taught extra, go to www.anixa.com or comply with Anixa on LinkedIn, X, Facebook and YouTube.
Ahead-Wanting Statements
Statements that aren’t historic reality could also be thought of forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements will not be statements of historic details, however moderately replicate Anixa’s present expectations regarding future occasions and outcomes. We typically use the phrases “believes,” “expects,” “intends,” “plans,” “anticipates,” “seemingly,” “will” and related expressions to establish forward-looking statements. Such forward-looking statements, together with these regarding our expectations, contain dangers, uncertainties and different elements, a few of that are past our management, which can trigger our precise outcomes, efficiency or achievements, or trade outcomes, to be materially totally different from any future outcomes, efficiency, or achievements expressed or implied by such forward-looking statements. These dangers, uncertainties and elements embody, however will not be restricted to, these elements set forth in “Merchandise 1A – Danger Elements” and different sections of our most up-to-date Annual Report on Type 10-Okay in addition to in our Quarterly Studies on Type 10-Q and Present Studies on Type 8-Okay. We undertake no obligation to publicly replace or revise any forward-looking statements, whether or not because of new data, future occasions or in any other case, besides as required by regulation. You’re cautioned to not unduly depend on such forward-looking statements when evaluating the data introduced on this press launch.
Contact:
Mike Catelani
President, COO & CFO
408-708-9808
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-of-chinese-patent-covering-breast-cancer-vaccine-technology-302588477.html
SOURCE Anixa Biosciences, Inc.
